Document:

EX-10.1

Exhibit 10.1

Umbrella Agreement

Between:

	 	–	 	On one hand, MYMETICS Corporation (hereinafter MYMETICS), an American de jure
corporation with a head office located at 230 Park Avenue, New York 10169, United
States of America, represented by its European subsidiary MYMETICS MANAGEMENT, a
limited company and Swiss de jure corporation with a head office located at 14, rue de
la Colombière, Nyon, CH-1260, Switzerland
Acting on its own behalf as well as for any related company,
Duly represented by Mr. Christian ROCHET, President and Chief Operating Officer (CEO)
	 
	 	–	 	And on the other hand, PX’ THERAPEUTICS (hereinafter PX’ THERAPEUTICS), a
corporation with its head office at Zone Minatec Entreprises, 7 Parvis Louis Néel,
38040 Grenoble, France,
Acting on its own behalf as well as for any related company of the Protein’eXpert
Group,
Duly represented by Mr. Tristan ROUSSELLE, President and Chief Operating Officer (CEO)

1

 

     Whereas:

	 	(a)	 	MYMETICS designs and develops new vaccines and specifically an HIV
Candidate Vaccine which includes a Modified Antigen consisting in a recombinant
antigen derived from the Gp41 viral protein, as defined by the framework and
sequence established in Appendix 1.
	 
	 	(b)	 	PX’ THERAPEUTICS is a Biotechnology company specialized in molecular
protein engineering and the optimization of recombinant protein production
processes, and therefore possesses regarding the field of vaccine recombinant
proteins:

	 	o	 	General Know-how generally concerning engineering, the
improvement and recombinant Gp41 antigen accession/production processes,
including the Modified Antigen
	 
	 	o	 	And Specific and particular Know-how concerning the specific
aspects of the optimized accession/production process, including property and
quality control of the Modified Antigen.

	 	(c)	 	The Specific Know-how is the outcome of the partnership that has
existed since 2001 between PX’ THERAPEUTICS and MYMETICS, as materialized and
defined by the successive contracts identified and listed in Appendix 2.

Pursuant to the contracts identified and listed in Appendix 2, the Modified Antigen
belongs to MYMETICS, while the Specific Know-how remains the property of PX’
THERAPEUTICS. 

Pursuant to the contracts identified and listed in Appendix 2, in case MYMETICS or
any third party assign or legal representative exploits the Vaccine, MYMETICS or
said third party agrees to pay PX’ THERAPEUTICS royalties of [***] based on the
sales figures earned as a result of exploiting the Vaccine.
	 
	 	(d)	 	In view of the development of the Candidate Vaccine, including
pre-clinical and clinical tests of the latter, MYMETICS and PX’THERAPEUTICS wish
to define the terms of access to and exploitation of the General and Specific
Know-how, which is

2

 

	 	 	 	presently the property of PX’THERAPEUTICS in compliance with and as a complement to
the previous contracts identified and listed in Appendix 2.

The parties therefore agree on the following:

Section 1) Communication of General and Specific Know-how

The communication of the General and Specific Know-how by PX’ THERAPEUTICS will take place in the
two following phases:

1.1) Phase I – Written communication of the General Know-how and the Specific Know-how

The General and Specific Know-how that belong to PX’ THERAPEUTICS as of December 1st,
2008 is described completely and precisely in a Single Document (Document Unique) that make it
possible for any laboratory technician who is competent in biotechnology to reproduce them in
accordance with the stated performances (including quality and productivity standards). The items
of General Know-how contained in said Single Document will be indicated as such by PX’
THERAPEUTICS. The Single Document shall be delivered by PX’ THERAPEUTICS to MYMETICS no later than
2 months following the date of execution of the Agreement, for which MYMETICS acknowledges receipt.

1.2) Phase II – Experimental communication of the General Know-how and Specific Know-how

Phase II will occur following delivery of the Single Document. The General Know-how and the
Specific Know-how that was the property of PX’THERAPEUTICS as of December 1st, 2008
shall be communicated by PX’ THERAPEUTICS to MYMETICS, by means of PX’THERAPEUTICS training the
staff of MYMETICS, on one hand, and scientific and technical assistance of PX’ THERAPEUTICS
provided to MYMETICS, on the other hand, all in accordance with practical terms and conditions that
remain to be defined.

More specifically, the different biological material, including modified cell strains/cultures that
are part of the Specific Know-how and that are required

3

 

to access/produce the Modified Antigen by recombinant means, shall be submitted by PX’ THERAPEUTICS
under the name of MYMETICS, to a known collection, such as CNCM in France, with access rights
exclusively reserved for MYMETICS.

Section 2) Property and Exploitation of the General and Specific Know-how

2.1) Property

On condition precedent defined in Section 4, PX’ THERAPEUTICS assigns to MYMETICS, which accepts,
full property of the Specific Know-how, definitively and irrevocably.

Consequently, PX’ THERAPEUTICS is prohibited from:

	 	–	 	Communicating the Specific Know-how to a third party, including under a
confidential form, as well as divulging and making public all or part of said Specific
Know-how,
	 
	 	–	 	Exploiting, directly or indirectly, by itself or for a third party, the
Specific Know-how; except when the exploitation of said Specific Know-how is required
to implement subcontracting by MYMETICS to PX’ Pharma (a company related to PX’
THERAPEUTICS) of batches of the Modified Antigen,
	 
	 	–	 	Safeguarding all or part of the Specific Know-how, under its own name or the
name of a third party, by depositing one or several applications for a patent, whether
in France or abroad.

Consequently, subject to the existing contracts listed in Appendix 2, MYMETICS may dispose of and
administer the Specific Know-how (including the Modified Antigen) as it pleases, completely
independently of PX’ THERAPEUTICS and may more specifically elect to safeguard or not all or part
of said Specific Know-how by depositing one or several patents under its name or the name of a
third party; PX’ THERAPEUTICS not having any exploitation right nor obligation whatsoever of
non-opposition against MYMETICS to said patents, whether on its own behalf or for a third party
that is a partner of PX’ THERAPEUTICS, including in the field of producing the Gp41 antigen and/or
modified Gp41 antigens other than the Modified Antigen.

2.2) License

4

 

The General Know-how remains the full and entire property of PX’ THERAPEUTICS.

On condition precedent defined in Section 4, PX’ THERAPEUTICS grants MYMETICS a non-exclusive
license, with the option of granting sub-licenses, for all countries, of the General Know-how,
solely for the purposes of MYMETICS exploiting the Specific Know-how, inasmuch as exploitation of
the Specific Know-how requires or involves exploitation of the General Know-how.

This license is granted for a [***] term as of the date of execution of the Contract. Upon expiry
of this term, the license is renewable upon request by MYMETICS and in no case removable by PX’
THERAPEUTICS.

As of the date of execution of this agreement, no license concerning the general know-how other
than those already granted may be granted by PX’ THERAPEUTICS to a third party in the field of
vaccines.

Subject to and beyond the license on General Know-how granted to MYMETICS, PX’ THERAPEUTICS may
dispose of the General Know-how as it pleases. Consequently, beyond the license on General Know-how
that is granted to it, MYMETICS is forbidden:

	 	–	 	To communicate the General Know-how to a third party, including
confidentially, as well as to divulge and publish all or part of said General
Know-how,
	 
	 	–	 	Exploit, directly or indirectly, by itself or for a third party the General
Know-how,
	 
	 	–	 	Safeguard all or part of the General Know-how, under its own name or in the
name of a third party, by depositing one or several applications for a patent, whether
in France or abroad.

Consequently, subject to the license on General Know-how granted to MYMETICS, PX’ THERAPEUTICS may
dispose of and administer the General Know-how as it pleases, totally independently from MYMETICS,
and more specifically safeguard or not all or part of said General Know-how by depositing one or
several patent(s) under its own name or in the name of a third party; MYMETICS disposing
automatically, and without extra financial consideration beyond the one defined below, of a right
to exploit said patents, in all countries, within the limits and on the conditions of the license
for General Know-how granted to MYMETICS by PX’

5

 

THERAPEUTICS, that is inasmuch as the exploitation of the Specific Know-how requires or involves
the exploitation of said patents.

Section 3) Financial Conditions

In consideration of the assignment described in Section 2.1 of the Specific Know-how, MYMETICS pays
PX’ THERAPEUTICS the sum of [***], duty free, in five installments, that is:

	 	–	 	One first installment of [***] upon execution of this Agreement,
	 
	 	–	 	A second installment of [***] no later than three months following the date
of execution of the Agreement subject to Section 4,
	 
	 	–	 	A third installment of [***], following completion of training of MYMETICS
staff; see Section 1.1,
	 
	 	–	 	And a fourth installment of [***] on the date of validation of the Vaccine
Candidate; “validation” means MYMETICS has deposited with the supervisory authority
involved an IMPD (or IND) file to carry out the first clinical tests of the Vaccine.

Apart from these installments, MYMETICS confirms its obligation to pay a royalty of [***] provided
for in Subsection (c) of the preamble of this Agreement.

In consideration of the assignment of the license on General Know-how, in accordance with Section
2.2, MYMETICS shall pay PX’ THERAPEUTICS a yearly royalty of [***] duty free, payable upon the
expiry of the term and for at least five years as of the anniversary date of the execution of this
Agreement. This royalty will be deductible from the exploitation royalty of [***] provided for in
Subsection (c) in the preamble of this Agreement as soon as the Vaccine is exploited and as an
annual minimum exploitation royalty of [***] is reached.

Section 4) Early Termination

In the month following the submission of the Single Document, MYMETICS has the right to terminate
unilaterally the latter, by means of a registered letter with acknowledgment of receipt, without
compensation due in this respect by MYMETICS to PX’ THERAPEUTICS.

In the event of an early termination of this Agreement by MYMETICS:

6

 

	 	–	 	The first installment according to Section 3.1 remains definitively earned by
PX’ THERAPEUTICS,
	 
	 	–	 	The assignment of the Specific Know-how according to Section 2.1 and the
licensing of the General Know-how according to Section 2.2 are automatically
cancelled.
	 
	 	–	 	The Specific Know-how and General Know-how remain the entire property of PX’
THERAPEUTICS, MYMETICS following in respect of the same the obligations retained
against it by virtue of Section 2.2.

Section 5) Benefits of PX’ THERAPEUTICS

5.1 Notwithstanding the fulfillment of this Agreement, PX’ THERAPEUTICS and MYMETICS remain
partners regarding the accession/production of any peptide/protein making up a variation of the
Modified Antigen:

	 	–	 	MYMETICS designing or defining said peptide/protein
	 
	 	–	 	And PX’ THERAPEUTICS defining, as a subcontractor, the process to implement
in order to access/produce said peptide/protein, excluding any design or co-design of
the latter.

5.2 Any benefits of PX’ THERAPEUTICS such as defined above shall be subject to an agreement with
MYMETICS that will be distinct from this Agreement, and defining specifically the earnings of PX’
THERAPEUTICS.

5.3 Nevertheless, it is agreed a priori between MYMETICS and PX’ THERAPEUTICS that all specific
aspects of the accession/production process, including property and quality control, of any
peptide/protein making up a variation of the Modified Antigen, for which accession is entrusted to
and accomplished by PX’ THERAPEUTICS subcontracting from MYMETICS, are part of and add to the
Specific Know-how as understood in this Agreement and as such are communicated and assigned by PX’
THERAPEUTICS to MYMETICS, without any consideration beyond that provided for in Section 3, subject
to Section 5.2.

Section 6) Guarantees

PX’ THERAPEUTICS states and guarantees that the terms and conditions granted by virtue of
this Agreement to MYMETICS, especially those described in Section 5 are and shall be those
granted

7

 

to any third party co-operating with PX’ THERAPEUTICS in the field of vaccine therapy
against HIV.

PX’ THERAPEUTICS states and guarantees furthermore that it is totally at liberty to execute
this Agreement; specifically, that carrying out the latter does not infringe upon any
commitment or any obligation contracted previously by PX’ THERAPEUTICS.

As for the rest, PX’ THERAPEUTICS guarantees that the General Know-how and Specific
Know-how make it possible to access/produce the Modified Antigen in accordance with
Appendix 1.

The parties may complete the provisions stipulated in this umbrella agreement by drafting
supplementary agreements or standard agreements signed by both parties.

Made in Grenoble, France, in three original copies, including one for tax purposes.

For PX’ THERAPEUTICS, Mr. Tristan ROUSSELLE, as Chief Executive Officer

/s/ Tristan Rousselle

For MYMETICS, Mr. Christian ROCHET, as Chief Operating Officer

/s/ Christian Rochet

List of appendices to establish for the contract:

Appendix 1: Structure and Sequence of the Modified Antigen

Appendix 2: Identification and List of Successive contracts between MYMETICS and PX’
THERAPEUTICS,

8

 

Appendix 1: Structure and Sequence of the Modified Antigen

Mymetics and PX’ Therapeutics have worked on several generations of the Modified Antigen
since they began co-operating together. The [***] is the subject of current developments.

[***]

Appendix 2

Scientific Collaboration Agreement Gp41, as of December 1st, 2002.

Research Contract, as of September 15th, 2003.

Research Contract, as of March 15th, 2004.

Research Contract, as of September 1st, 2004.

Research Contract pending execution C-MYM 060707

9EX-10.1

Exhibit 10.1

AMENDED AND RESTATED

AGREEMENT

          This Amended and Restated Agreement (this “Agreement”) made as of this 26th day of December,
2008 by and between Black Box Corporation, a Delaware corporation (the “Corporation”), and Michael
McAndrew, an individual residing in the Commonwealth of Pennsylvania and an executive of the
Corporation (the “Executive”).

WITNESSETH:

          WHEREAS, the Board of Directors of the Corporation had previously determined that it is in the
best interests of the Corporation to enter into an agreement with the Executive providing for
certain payments and benefits to the Executive; and

          WHEREAS, the parties desire to amend and restate the prior agreement in order to ensure that
the payments and benefits due thereunder remain excepted from coverage under Section 409A (“Section
409A”) of the Internal Revenue Code of 1986, as amended (the “Code”);

          NOW, THEREFORE, the parties hereto, each intending to be legally bound hereby, agree as
follows:

	1.	 	Definition of Terms The following terms when used in this Agreement shall have the
meaning hereafter set forth:

	 	(a)	 	“Annual Salary Adjustment Percentage” shall mean the mean average
percentage increase in base salary for all executive officers of the Corporation
during the two full calendar years immediately preceding the time to which such
percentage is being applied; provided, however, that if after a
Change-in-Control, as hereinafter defined, there should be a significant change
in the number of executive officers of the Corporation or in the manner in which
they are compensated, then the foregoing definition shall be changed by
substituting for the phrase “executive officers of the Corporation” the phrase
“persons then performing the functions formerly performed by the executive
officers of the Corporation.”

-1-

 

	 	(b)	 	“Cause for Termination” shall mean:

	 	(i)	 	the deliberate and intentional failure by the
Executive to devote substantially the Executive’s entire business time
and best efforts to the performance of the Executive’s duties (other than
any such failure resulting from the Executive’s incapacity due to
physical or mental illness or disability);
	 
	 	or	 	
	 
	 	(ii)	 	engaging by the Executive in gross misconduct
materially and demonstrably injurious to the Corporation;
	 
	 	or	 	
	 
	 	(iii)	 	the conviction of the Executive of, or the entry
of a plea of guilty or Nolo Contendre by the Executive to, a crime
involving an act of fraud or embezzlement against the Corporation or the
conviction of the Executive of, or the entry of a plea of Nolo Contendre
by the Executive to, any felony involving moral turpitude;
	 
	 	or	 	
	 
	 	(iv)	 	the Executive’s material breach of Section 4 or
Section 8 hereof which continues for ten (10) days after receiving
written notice thereof from the Corporation or the Executive’s willful
failure to comply with instructions of the Board of Directors of the
Corporation provided that such instructions would not give rise to Good
Reason for Termination.

	 	 	 	For purposes of this definition, no act, or failure to act, on the Executive’s
part shall be considered “deliberate and intentional” or to constitute gross
misconduct unless done, or omitted to be done, by the Executive not in good
faith and without reasonable belief that the Executive’s action or omission
was in the best interests of the Corporation.

	 	(c)	 	“Change-in-Control” shall mean a change in control of the
Corporation of such a nature that it would be required to be reported by the
Corporation in response to Item 6(e) of Schedule 14A of Regulation 14A
promulgated under the Securities Exchange Act of 1934, as in effect on the date
hereof (“Exchange Act”); provided, however, that:

-2-

 

	 	(i)	 	without respect to the foregoing, such a change in
control shall be deemed to have occurred if any “person” (as such term is
used in sections 13(d) and 14(d)(2) of the Exchange Act) or any “group”
(as such term is defined in Rule 13d-5(b) promulgated under the Exchange
Act), is or becomes the beneficial owner, directly or indirectly, of
securities of the Corporation representing twenty percent (20%) or more
of the combined voting power of the Corporation’s then outstanding
securities coupled with or followed by the existence of a majority of the
board of directors of the Corporation consisting of individuals other
than individuals who either were directors of the Corporation at least
one year prior to or were nominated by those individuals who were
directors of the Corporation at least one year prior to such person or
group becoming a beneficial owner, directly or indirectly, of securities
of the Corporation representing 20% or more of the combined voting power
of the Corporation’s then outstanding securities;
	 
	 	and 	 	
	 
	 	(ii)	 	without respect to the foregoing, if the
Corporation shall sell all or substantially all of its assets or shall
merge, consolidate or reorganize with another company, then such a change
in control shall be deemed to have occurred if (x) upon conclusion of the
transaction less than fifty-one percent (51%) of the outstanding
securities entitled to vote generally in the election of directors of the
acquiring company or resulting company are owned by persons who were the
stockholders of the Corporation generally prior to the transaction and
following the transaction a majority of the board of directors of the
acquiring company or resulting company consists of individuals other than
individuals who either were directors of the Corporation at least one
year prior to or were nominated by those individuals who were directors
of the Corporation at least one year prior to such sale, merger,
consolidation or reorganization or (y) following the transaction a person
or group (as described in subclause (i) above) would be a beneficial
owner, directly or indirectly, of securities of the acquiring company or
resulting company representing 20% or more of the combined voting power
of the acquiring company’s or resulting company’s then outstanding
securities as described in subclause (i) above and a majority of the
board of directors of the acquiring company or resulting company consists
of individuals other than individuals who either were directors of the
Corporation at least one year prior to or were

-3-

 

	 	 	 	nominated by those individuals who were directors of the Corporation
at least one year prior to such sale, merger, consolidation or
reorganization.

	 	(d)	 	“Date of Termination” shall mean:

	 	(i)	 	if the Executive’s employment is terminated for
Disability, the date that a Notice of Termination is given to the
Executive;
	 
	 	(ii)	 	if the Executive’s employment terminates due to the
Executive’s death or Retirement, the date of death or Retirement,
respectively;
	 
	 	(iii)	 	if the Executive decides to terminate employment
upon Good Reason for Termination, the date specified by the Executive in
a Notice of Termination, which date must be within sixty (60) days after
the expiration of the Notice Period (as defined in Section 3(c) below);
or
	 
	 	(iv)	 	if the Executive’s employment is terminated for any
other reason, the date on which a termination becomes effective pursuant
to a Notice of Termination or, if no Notice of Termination is provided,
the date that the Executive’s employment was terminated.

	 	(e)	 	“Disability” shall mean such incapacity due to physical or mental
illness or injury as causes the Executive to be unable to perform the Executive’s
duties with the Corporation during 90 consecutive days or 120 days during any six
month period.
	 
	 	(f)	 	“Good Reason for Termination” shall mean a material negative change
in the Executive’s service relationship with the Corporation and any Affiliate
(as defined in this Section 1(f) below) of the Corporation, taken as a whole,
without Executive’s consent, on account of one or more of the following
conditions:

	 	(i)	 	A material diminution in Executive’s base
compensation;
	 
	 	(ii)	 	A material diminution in Executive’s authority,
duties or responsibilities; or
	 
	 	(iii)	 	A change in the geographic location at which
Executive must report to and perform the majority of Executive’s
services of more than fifty (50) miles.

-4-

 

	 	 	 	“Affiliate” shall mean, with respect to any person or legal entity, any
other person or legal entity controlling, controlled by or under common
control with such person or legal entity.
	 
	 	(g)	 	“LTIP Plan” shall mean an incentive compensation plan of the
Corporation which would pay bonuses to the Executive based upon the achievement
of specified goals during or at the end of an award period of more than one year
(such as a three year incentive compensation plan).
	 
	 	(h)	 	“Notice of Termination” shall mean a written statement which sets
forth the specific reason for termination and, if such is claimed to be Cause for
Termination or Good Reason for Termination, in reasonable detail the facts and
circumstances thereof.
	 
	 	(i)	 	“Options” shall mean any stock options issued pursuant to any
present or future stock option plan of the Corporation.
	 
	 	(j)	 	“Retirement” shall mean a termination of the Executive’s employment
after age 65 or in accordance with any mandatory retirement arrangement with
respect to an earlier age agreed to by the Executive.
	 
	 	(k)	 	“Stock Awards” shall mean any stock-based awards, other than
Options, including any stock appreciation rights, restricted stock awards, or
performance stock awards, issued pursuant to any present or future stock plan of
the Corporation.

	2.	 	Termination by the Corporation Due to Cause for Termination. Should the Board of
Directors of the Corporation determine that Cause for Termination exists, the Board of
Directors of the Corporation by resolution duly adopted may at that time or during a period of
two months thereafter terminate the Executive’s employment due to Cause for Termination by
delivering a Notice of Termination. If the Board of Directors of the Corporation fails to
duly adopt within such two month period a resolution terminating the Executive’s employment,
then the Corporation shall be deemed to have waived its right to terminate the Executive due
to those circumstances which constituted the Cause for Termination previously found to exist
by the Board.

	3.	 	Payments Following Termination of Employment After Change-in-Control.

-5-

 

	 	(a)	 	If during the term of this Agreement the Executive’s employment
with the Corporation shall be terminated:

	 	(i)	 	due to the Executive’s death or Disability,
	 
	 	(ii)	 	by the Executive at any time prior to a
Change-in-Control,
	 
	 	(iii)	 	by the Executive following a Change-in-Control
other than the Executive’s having terminated for Good Reason for
Termination,
	 
	 	(iv)	 	by the Corporation at any time prior to a Change-in-Control, or
	 
	 	(v)	 	by the Corporation following a Change-in-Control in accordance
with Section 2 hereof or in accordance with
Retirement,

	 	 	 	then the Corporation shall have no obligations hereunder to the Executive from
and after the Date of Termination and the only obligations of the Corporation
to the Executive shall be in accordance with any other employment agreement
applicable to the Executive and the then various policies, practices and
benefit plans of the Corporation.
	 
	 	(b)	 	If during the term of this Agreement a Change-in-Control shall have
occurred and the Executive’s employment shall have been involuntarily terminated
on or before the second anniversary of the date of the Change-in-Control other
than under the circumstances above described in subsection 3(a) (for example, a
termination by the Executive for Good Reason for Termination within the foregoing
period following a Change-in-Control shall entitle the Executive to the payments
set forth in this subsection), then the Corporation shall pay the Executive on or
before the sixtieth (60th) day following the Date of Termination the following
sums:

	 	(i)	 	in cash any unpaid portion of the Executive’s full
base salary for the period from the last period for which the Executive
was paid to the Date of Termination; and
	 
	 	(ii)	 	an amount in cash as liquidated damages for lost
future remuneration equal to the sum of

(A) the product obtained by multiplying:

(1) the lesser of

-6-

 

(i) two (2.0), or

(ii) a number equal to the number of calendar
months remaining from the Date of Termination to
the date on which the Executive is 65 years of age
(or, if earlier, the age agreed to by the Executive
pursuant to any prior arrangement) divided by
twelve,

times

(2) the sum of

(i) the greater of

(x) the Executive’s annual base salary for the
year in effect on the Date of Termination,

(y) in the case of termination by the
Executive for Good Reason for Termination, the
Executive’s annual base salary in effect on
the date immediately preceding the date of the
earliest event which gave rise to the
termination by the Executive for Good Reason
for Termination,

or

(z) the Executive’s annual base salary for the
year in effect on the date of the
Change-in-Control,

plus

(ii) the greater of

(x) one third (1/3) of the aggregate cash
bonuses or awards (including any payments
under an LTIP Plan) received by the Executive
as incentive compensation or bonus during the
three calendar years immediately preceding the
Date of Termination

-7-

 

(y) in the case of termination by the
Executive for Good Reason for Termination, one
third (1/3) of the aggregate cash bonuses or
awards (including any payments under an LTIP
Plan) received by the Executive as incentive
compensation or bonus during the three
calendar years immediately preceding the date
of the earliest event which gave rise to the
termination by the Executive for Good Reason
for Termination,

or

(z) one third (1/3) of the aggregate cash
bonuses or awards (including any payments
under an LTIP Plan) received by the Executive
as incentive compensation or bonus for the
three calendar years immediately preceding the
date of the Change-in-Control,

plus

(B) if the Executive immediately preceding the date of the
Change-in-Control is a participant in an LTIP Plan and the award
period has not been completed prior to the date of the
Change-in-Control, an amount equal to

(1) the total cash
award or bonus which would have been received by the
Executive under such LTIP Plan assuming that, in
addition to any goals met on or before the date of the
Change-in-Control, all goals that were to be measured
after the date of the Change-in-Control were achieved
and the Executive remained in the employ of the
Corporation at all relevant times under the LTIP Plan,

less

(2) any portion of
the cash award or bonus for that award period
previously paid to the Executive pursuant to such LTIP
Plan.

-8-

 

	 	(c)	 	In order for the Executive to terminate for Good Reason for
Termination under this Agreement, (i) the Executive must deliver a Notice of
Termination to the Corporation at 1000 Park Drive, Lawrence, PA 15055, Attn:
General Counsel, and within ninety (90) days of the event constituting Good
Reason for Termination, (ii) the event must remain uncorrected during the Notice
Period and (iii) the Date of Termination must occur within sixty (60) days after
the expiration of the Notice Period. “Notice Period” means the thirty (30) days
following the date that Executive notifies the Corporation in writing of
Executive’s intent to terminate employment for Good Reason for Termination.

	4.	 	Nondisclosure of Information.

	 	(a)	 	Executive acknowledges that the Corporation has invested and will
continue to invest considerable resources in the research, development and
advancement of the Corporation’s business, which investment has or may result in
the generation of proprietary, confidential and/or trade secret data,
information, techniques and materials, tangible and intangible, which properly
belong to the Corporation or in which the Corporation has an interest. Executive
acknowledges and agrees that it would be unlawful for Executive to appropriate,
to attempt to appropriate, or to disclose to anyone or use for a third party’s
benefit such data, information, techniques or materials, subject to the
following:

	 	(i)	 	Executive acknowledges that the following
constitute protectable confidential, trade secret or otherwise
proprietary information of the Corporation or of a third party: all
computer software and firmware and computer aided mechanisms related to
the foregoing, files, programs, data or information received by the
Corporation from a customer or prospective customer of the Corporation if
such is confidential or proprietary to the customer, data base management
systems or other instrumentations, any proposals for development, any
reports on findings of tests, investigative studies, consultations or the
like, pricing policies, budgets, customer lists, strategic plans (whether
or not communicated in writing), marketing and sales information, all
written documents not generally in the public domain, any and all copies
or imitations of the foregoing, and all other confidential, trade secret
or proprietary information, whether or not copyrighted or patented and
whether created solely by Executive, jointly with others, or solely by
others.

-9-

 

	 	(ii)	 	For purposes of this Section 4, all confidential,
proprietary, or trade secret information enumerated or mentioned in
Section 4(a)(i) is hereinafter referred to as “Information”. Any
restrictions on disclosure and use of the Information will apply to all
copies of the Information, whether in whole or in part.
	 
	 	(iii)	 	During the term of this Agreement and at all times
after termination of this Agreement, unless authorized in writing by the
Corporation, the Executive will not:

	 	(1)	 	use for the Executive’s benefit
or advantage the Information, or
	 
	 	(2)	 	use the Information for the
benefit or advantage of any third party, or
	 
	 	(3)	 	disclose or cause to be disclosed
the Information or authorize or permit such disclosure of the
Information to any unauthorized third party, or
	 
	 	(4)	 	use the Information in any manner
which is intended to injure or cause loss, whether directly or
indirectly, to the Corporation.

	 	(iv)	 	The Executive will not be liable for the disclosure
of Information which:

	 	(1)	 	is in the public domain generally
and as such becomes known to Executive through no wrongful act
or breach of this Agreement; or
	 
	 	(2)	 	is received rightfully by
Executive from a third party having a lawful right to possess
and to release the Information, provided the Executive agrees to
promptly notify the Corporation if the Executive suspects that
the information possessed by the third party is within the
meaning of Information under this Agreement.

	 	(v)	 	In any judicial proceeding, it will be presumed
that the Information constitutes protectable trade secrets, and the
Executive will bear the burden of proving that any Information is
publicly or rightfully known by the Executive.

-10-

 

	 	(vi)	 	The Executive will surrender to the Corporation at
any time upon request, and upon termination of the Executive’s employment
with the Corporation for any reason, all written or otherwise tangible
documentation representing or embodying the Information, in whatever
form, whether or not copyrighted, patented, or protected as a mask work,
and any copies or imitations of the Information, whether or not made by
the Executive.
	 
	 	(vii)	 	The Executive agrees to be available upon request
for consultation after termination of employment to provide information
and details with respect to any work or activity performed or materials
created by the Executive alone or with others during the Executive’s
employment by the Corporation. The Executive will be reimbursed for
these services.

	 	(b)	 	Any and all creations, developments, discoveries, inventions, works
of authorship, enhancements, modifications and improvements, including without
limitation computer programs, data bases, data files and the like, (hereinafter
collectively referred to as “Development” or “Developments”), whether or not the
Developments are copyrightable, patentable, protectable as mask works or
otherwise protectable (such as by contract or implied duty), and whether
published or unpublished, conceived, invented, developed, created or produced by
the Executive alone or with others during the term of the Executive’s employment,
whether or not during working hours and whether on the Corporation’s premises or
elsewhere, will be the sole and exclusive property of the Corporation if the
Development is:

	 	(i)	 	connected with the Corporation in any way, or
	 
	 	(ii)	 	within the scope of the Executive’s duties assigned
or implied in accordance with the Executive’s position, or
	 
	 	(iii)	 	a product, service, or other item which would be
in competition with the products or services offered by the Corporation
or which is related to the Corporation’s products or services, whether
presently existing, under development, or under active consideration, or
	 
	 	(iv)	 	in whole or in part, the result of the Executive’s
use of the Corporation’s resources, including without limitation
personnel, computers, data bases, communications facilities, word
processing systems, programs, office facilities or otherwise.

-11-

 

	 	 	 	During the term of the Executive’s employment with the Corporation and, if the
Corporation should then so request, after termination of such employment, the
Executive agrees to assign and does hereby assign to the Corporation all
rights in the Developments created by the Executive alone or with others
during the term of the Executive’s employment, and all rights in any
trademarks, copyrights, patents, trade secrets and analogous intellectual
property rights and any applications for registration for same, of the United
States and such foreign countries as the Corporation may designate which are
related to the Developments, including without limitation all accompanying
goodwill and the right to sue for infringement or misappropriation and to
receive all proceeds related to any judgment or settlement of same. The
Executive agrees to execute and deliver to the Corporation any instruments the
Corporation deems necessary to vest in the Corporation sole title to and all
exclusive rights in the Developments created by the Executive alone or with
others during the term of the Executive’s employment, and in all related
trademarks, copyrights, mask work protection rights, and/or patent rights so
created during the term of employment. The Executive agrees to execute and
deliver to the Corporation all proper papers for use in applying for,
obtaining, maintaining, amending and enforcing all such trademarks,
copyrights, patents or such other legal protections as the Corporation may
desire. The Executive further agrees to assist fully the Corporation or its
nominees in the preparation and prosecution of any trademark, copyright, mask
work protection, patent, or trade secret arbitration or litigation. The
Executive shall be reimbursed on a reasonable hourly basis consistent with the
compensation provided for herein for the Executive’s services rendered
following termination of employment.

	 	(c)	 	The Executive’s obligations and covenants in this Section 4 will be
binding upon the Executive’s heirs, legal representatives, successors and
assigns.
	 
	 	(d)	 	The Corporation and the Executive agree that the rights conveyed by
this Agreement are of a unique and special nature. The Executive and the
Corporation agree that any violation of this Section 4 will result in immediate
and irreparable harm to the Corporation and that in the event of any actual or
threatened breach or violation of any of the provisions of this Section 4, the
Corporation will be entitled as a matter of right to an injunction or a decree of
specific performance without bond from any equity court of competent
jurisdiction. The Executive waives the right to assert the defense that such
breach or violation can be compensated adequately in damages in an action at law.
Nothing in this Agreement will be construed as prohibiting the

-12-

 

	 	 	 	Corporation from pursuing any other remedies at law or in equity available to
it for such breach or violation or threatened violation.

	5.	 	Medical Insurance or Similar Benefit Plans. If the Executive’s employment should
terminate under such circumstance as entitles the Executive to receive payments pursuant to
Section 3(b) hereof, then, to the extent permitted by applicable law and the medical insurance
and benefits policies to which Executive is entitled to participate, Employer shall maintain
Executive’s paid coverage for health insurance (through the payment of Executive’s COBRA (as
defined below) premiums) until the earlier to occur of: (a) Executive attaining the age of 65,
(b) the date Executive is provided by another employer benefits substantially comparable to
the benefits provided by the above-referenced medical plan (which Executive must provide
prompt notice with respect thereto to the Employer) or (c) the expiration of the COBRA
Continuation Period (as defined below). During the applicable period of coverage described in
the foregoing sentence, Executive shall be entitled to benefits, on substantially the same
basis as would have otherwise been provided had Executive not been terminated and Employer
will have no obligation to pay any benefits to, or premiums on behalf of, Executive after such
period ends. To the extent that such benefits are available under the above-referenced
medical plan and Executive had such coverage immediately prior to termination of employment,
such continuation of benefits for Executive shall also cover Executive’s dependents for so
long as Executive is receiving benefits under this section. The COBRA Continuation Period for
medical insurance under this section shall be deemed to run concurrently with the continuation
period federally mandated by COBRA (generally 18 months), or any other legally mandated and
applicable federal, state, or local coverage period for benefits provided to terminated
employees under the medical plan. For purposes of this Agreement, (a) “COBRA” means the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and (b) “COBRA
Continuation Period” shall mean the continuation period for medical insurance to be provided
under the terms of this Agreement which shall commence on the first day of the calendar month
following the month in which the date of termination falls and generally shall continue for an
18 month period.

	6.	 	Other Employment. In the event of a termination of employment under the
circumstances above described in Section 3(b) hereof, the Executive shall have no duty to seek
any other employment after termination of the Executive’s employment with the Corporation and
the Corporation hereby waives and agrees not to raise or use any defense based on the position
that the Executive had a duty to mitigate or reduce the amounts due the Executive hereunder by
seeking other employment whether suitable or unsuitable and should the Executive obtain other
employment, then the only effect of such on the obligations of the Corporation hereunder shall
be that the Corporation shall be entitled to credit against any payments which would

-13-

 

		 	otherwise be made pursuant to Sections 5(a) or 5(b) hereof, any comparable payments to
which the Executive is entitled under the employee benefit plans maintained by the
Executive’s other employer or employers in connection with services to such employer
or employers after termination of the Executive’s employment with the Corporation.

	7.	 	Stock Awards and Options. If the Executive’s employment should terminate under the
circumstances described in Section 3(a) hereof, the Executive’s rights, if any, with respect
to any outstanding Stock Awards and/or Options shall be governed by the plans and any related
agreements pursuant to which such Stock Awards and/or Options were granted. If the
Executive’s employment should terminate under such circumstances as entitle the Executive to
receive payments pursuant to Section 3(b) hereof, then, with respect to each outstanding
Option or Stock Award which did not immediately vest and/or become exercisable upon the
occurrence of a Change-in-Control, such Stock Award or Option shall remain outstanding in
accordance with its terms provided that in any event it shall automatically vest upon
termination of employment and/or become and remain exercisable at any time after termination
of employment until the stated expiration date contained in the grant for such Stock Award or
Option, provided that the expiration date of any such Option or Stock Award may not exceed ten
years from the date of grant.

	8.	 	Noncompetition. During the period of employment of Executive by the Corporation and
for five (5) years thereafter, the Executive will not, in any geographic area in which the
Corporation is offering its services and products, without the prior written consent of the
Corporation:

	 	(a)	 	directly or indirectly engage in,
	 
	 	(b)	 	assist or have an active interest in (whether as proprietor,
partner, investor, shareholder, officer, director or any type of principal
whatsoever), or
	 
	 	(c)	 	enter the employ of, or act as agent for, or advisor or consultant
to, any person, firm, partnership, association, corporation or business
organization, entity or enterprise which is or is about to become directly or
indirectly engaged in,

	 	 	any business which is competitive with any business of the Corporation or any
subsidiary or affiliate thereof in which Executive is or was engaged; provided,
however, that the foregoing provisions of this paragraph 8 are not intended to
prohibit and shall not prohibit Executive from purchasing, for investment, not in
excess of 1% of any class of stock or other corporate security of any company which is
registered pursuant to Section 12 of the Securities Exchange Act of 1934.

-14-

 

	 	 	Executive acknowledges that the breach by the Executive of the provisions of this
Section 8 would cause irreparable injury to the Corporation, acknowledges and agrees
that remedies at law for any such breach will be inadequate and consents and agrees
that the Corporation shall be entitled, without the necessity of proof of actual
damage, to injunctive relief in any proceedings which may be brought to enforce the
provisions of this Section 8. Executive acknowledges and warrants that the Executive
will be fully able to earn an adequate livelihood for the Executive and the
Executive’s dependents if this Section 8 should be specifically enforced against the
Executive and that such enforcement will not impair the Executive’s ability to obtain
employment commensurate with the Executive’s abilities and fully acceptable to the
Executive.
	 
	 	 	If the scope of any restriction contained in this Section 8 is too broad to permit
enforcement of such restriction to its full extent, then such restriction shall be
enforced to the maximum extent permitted by law and Executive and the Corporation
hereby consent and agree that such scope may be judicially modified in any proceeding
brought to enforce such restriction.
	 
	9.	 	Terms. This Agreement shall be for an initial term of five years commencing on the
date hereof. This Agreement shall automatically renew for an additional term of one year
commencing on the fifth anniversary of the date hereof and for succeeding additional terms
each of one year on each succeeding anniversary thereof until and unless either party sends
written notice of non-renewal to the other party at least six months prior to a renewal date;
provided, however, that if a Change-in-Control shall occur during the initial or renewed term
of this Agreement, then this Agreement shall remain in effect until the second anniversary of
the date of the Change-in-Control.
	 
	10.	 	Miscellaneous.

	 	(a)	 	This Agreement shall be construed under the laws of the
Commonwealth of Pennsylvania.
	 
	 	(b)	 	This Agreement constitutes the entire understanding of the parties
hereto with respect to the subject matter hereof and may only be amended or
modified by written agreement signed by the parties hereto. The parties
acknowledge and agree that this Agreement supersedes, amends and restates in its
entirety, renders null and void and terminates that certain Agreement by and
between the parties dated May 15, 2007.
	 
	 	(c)	 	The Corporation will require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all of the

-15-

 

	 	 	 	business and/or assets of the Corporation, by agreement in form and substance
satisfactory to the Executive, to expressly assume and agree to perform this
Agreement in the same manner required of the Corporation and to perform it as
if no such succession had taken place. Failure of the Corporation to obtain
such agreement prior to the effectiveness of any such succession shall be a
breach of this Agreement and shall entitle the Executive to terminate
employment due to Good Reason for Termination. As used in this Agreement,
“Corporation” shall mean the Corporation as hereinbefore defined and any
successor to its business and/or assets as aforesaid which executes and
delivers the agreement provided for in this subsection (c) or which otherwise
becomes bound by all the terms and provisions of this Agreement by operation
of law.

	 	(d)	 	This Agreement shall inure to the benefit of and be enforceable by
the Executive and the Corporation and their respective legal representatives,
executors, administrators, successors, heirs, distributees, devisees and
legatees. If the Executive should die while any amounts would still be payable
to the Executive hereunder if the Executive had continued to live, all such
amounts, unless otherwise provided herein, shall be paid in accordance with the
terms of this Agreement to the Executive’s devisee, legatee or other designee or,
if there be no such designee, to the Executive’s estate.
	 
	 	(e)	 	Any notice or other communication provided for in this Agreement
shall be in writing and, unless otherwise expressly stated herein, shall be
deemed to have been duly given if mailed by United States registered mail, return
receipt requested, postage prepaid, addressed in the case of the Executive to the
Executive’s office at the Corporation with a copy to the Executive’s residence
and in the case of the Corporation to its principal executive offices, attention
of the Chief Executive Officer.
	 
	 	(f)	 	No provisions of this Agreement may be modified, waived or
discharged unless such waiver, modification or discharge is agreed to in writing
signed by the Executive and approved by resolution of the Board of Directors of
the Corporation. No waiver by either party hereto at any time of any breach by
the other party hereto of, or compliance with, any condition or provision of this
Agreement to be performed by such other party shall be deemed a waiver of similar
or dissimilar provisions or conditions at the same or at any prior or subsequent
time. No agreements or representations, oral or otherwise, express or implied,
with respect to the subject matter hereof have been made by either party which
are not set forth expressly in this Agreement. Nothing contained herein shall
impair the right of the Corporation to terminate the

-16-

 

	 	 	 	Executive’s employment, subject to making any payments required to be made
hereunder.

	 	(g)	 	The invalidity or unenforceability of any provisions of this
Agreement shall not affect the validity or enforceability of any other provision
of this Agreement, which shall remain in full force and effect.
	 
	 	(h)	 	This Agreement may be executed in one or more counterparts, each of
which shall be deemed to be an original but all of which together will constitute
one and the same instrument.
	 
	 	(i)	 	If litigation should be brought to enforce, interpret or challenge
any provision contained herein, the prevailing party in such litigation, if any,
shall be entitled to its reasonable attorney’s fees and disbursements and other
costs incurred in such litigation and to interest on any money judgment obtained
calculated at the prime rate of interest in effect from time to time at Citizen’s
Bank, N.A. (or its successor), from the date that the payment should have been
made under this Agreement.
	 
	 	(j)	 	Excise Taxes.

(i) For purposes of this subsection 10(j), (1) a Payment shall mean any
payment or distribution in the nature of compensation to or for the benefit of
the Executive, whether paid or payable pursuant to this Agreement or
otherwise; (2) Agreement Payment shall mean a Payment paid or payable pursuant
to this Agreement (disregarding this subsection 10(j)); (2) Net After Tax
Receipts shall mean the Present Value of a Payment net of all taxes imposed on
the Executive with respect thereto under Sections 1 and 4999 of the Code
determined by applying the highest marginal rate under Section 1 of the Code
applicable to the Executive’s taxable income for such year; (4) “Present
Value” shall mean such value determined in accordance with Section 280G(d) (4)
of the Code; and (5) “Reduced Amount” shall mean the greatest aggregate amount
of Payments, if any, which (x) is less than the sum of all Payments and (y)
results in aggregate Net After Tax Receipts which are greater than the Net
After Tax Receipts which would result if the aggregate Payments were made.

(ii) Anything in this Agreement to the contrary notwithstanding, in the event
PriceWaterhouseCoopers L.L.P. (or if PriceWaterhouseCoopers L.L.P. is the
audit firm for the Corporation at the time, another accounting firm of
nationally recognized standing selected by Executive) (the “Accounting Firm”)
shall determine that receipt of all Payments would subject the

-17-

 

Executive to tax under Section 4999 of the Code, it shall determine whether
some amount of Payments would meet the definition of a “Reduced Amount.” If
the Accounting Firm determines that there is a Reduced Amount, the aggregate
Agreement Payments shall be reduced to such Reduced Amount; provided, however,
that if the Reduced Amount exceeds the aggregate Agreement Payments, the
aggregate Payments shall, after the reduction of all Agreement Payments, be
reduced (but not below zero) in the amount of such excess. All determinations
made by the Accounting Firm under this Section shall be binding upon the
Corporation and the Executive and shall be made within 60 days of the
occurrence of an event which requires the Corporation to make payments to the
Executive under this Agreement. No later than two business days following the
making of this determination by the Accounting Firm, the Corporation shall pay
to or distribute for the benefit of the Executive such Payments as are then
due to the Executive under this Agreement and shall promptly pay to or
distribute for the benefit of the Executive in the future such Payments as
become due to the Executive under this Agreement. The Corporation or its
successor shall pay for the work done by the Accounting Firm. In the event
that the Accounting Firm is unable or unwilling to make the determinations to
be made under this subsection 10(j) or for any reason such determinations are
not made within 60 days of the occurrence of the event which requires the
Corporation to make payments to the Executive under this Agreement, the
Corporation shall make all Payments as are then due to the Executive without
reduction no later than two business days following the 60th day after the
occurrence of the event which required the Corporation to make payments to the
Executive under this Agreement.

(iii) While it is the intention of the Corporation and the Executive to reduce
the amounts payable or distributable to the Executive hereunder only if the
aggregate Net After Tax Receipts to the Executive would thereby be increased,
as a result of the uncertainty in the application of Section 4999 of the Code
at the time of the initial determination by the Accounting Firm hereunder, it
is possible that amounts will have been paid or distributed by the Corporation
to or for the benefit of the Executive pursuant to this Agreement which should
not have been so paid or distributed (“Overpayments”) or that additional
amounts which will not have been paid or distributed by the Corporation to or
for the benefit of the Executive pursuant to this Agreement could have been so
paid or distributed (“Underpayment”), in each case, consistent with the
calculation of the Reduced Amount hereunder. In the event that the Accounting
Firm, based either upon the assertion of a deficiency by the Internal Revenue
Service against the Corporation or the Executive which the Accounting Firm
believes has a high probability of success or controlling precedent or other
substantial

-18-

 

authority, determines that an Overpayment has been made, any such Overpayment
paid or distributed by the Corporation to or for the benefit of the Executive
shall be treated for all purposes as a loan ab initio to the Executive which
the Executive shall repay to the Corporation together with interest at the
applicable federal rate provided for in Section 7872(f) (2) of the Code;
provided, however, that no such loan shall be deemed to have been made and no
amount shall be payable by the Executive to the Corporation if and to the
extent such deemed loan and payment would not either reduce the amount on
which the Executive is subject to tax under Section 1 and Section 4999 of the
Code or generate a refund of such taxes. In the event that the Accounting
Firm, based upon controlling precedent or other substantial authority,
determines that an Underpayment has occurred, any such Underpayment shall be
promptly paid by the Corporation to or for the benefit of the Executive
together with interest at the applicable federal rate provided for in Section
7872(f) (2) of the Code.

	 	(k)	 	The payments to be made under this Agreement are intended to be
excepted from coverage under Section 409A and the regulations promulgated
thereunder and shall be construed accordingly. If the Corporation determines in
good faith that any amounts to be paid to Executive under this Agreement are
subject to Section 409A, the Corporation shall adjust or cause its Affiliate to
adjust the form and/or the timing of such payments as determined to be necessary
or advisable to be in compliance with Section 409A. If any payment must be
delayed to comply with Section 409A, such payment will be paid at the earliest
practicable date permitted by Section 409A. Notwithstanding any provision to the
contrary, to the extent that any amounts payable hereunder are subject to the
requirements of section 409A and are payable on account of termination of
employment, the payment of said amounts will be delayed for a period of six (6)
months after the termination date (or, if earlier, the death of the Participant)
for any Participant that is a “specified employee” (as defined in Section 409A).
Any payment that would otherwise have been due or owing during such six-month
period will be paid immediately following the end of the six-month period.
Notwithstanding any provision of this Agreement to the contrary, Executive
acknowledges and agrees that the Corporation and any Affiliate of the Corporation
shall not be liable for, and nothing provided or contained in this Agreement will
be construed to obligate or cause the Corporation or any Affiliate of the
Corporation to be liable for, any tax, interest or penalties imposed on Executive
related to or arising with respect to any violation of Section 409A.

-19-

 

     IN WITNESS WHEREOF, this Agreement has been executed on the date first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	BLACK BOX CORPORATION  
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Vicky L. Reed
	 	 	 	By:
	 	/s/ Terry Blakemore	 	 	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Title: Chief Executive Officer & President	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WITNESS:	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	/s/ Laura Cummins
	 	 	 	 	 	/s/ Michael McAndrew	 	 	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Michael McAndrew	 	 	 	 	 	 

-20-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]